Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
研究の種類
研究の種類
段階
段階
- フェーズ 3
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Willing and able to provide informed consent and to participate in the study
- Age > or = 40 years at the time of the screening
- Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan
- Minimum of 2 subsegments appropriate for treatment
- MRCD questionnaire score of 2 or greater at screening
- Failure of medical therapy to provide relief of symptoms
Spirometry 15 minutes after administration of bronchodilator (BOTH):
- FEV1 < 50 % predicted.
- FEV1/FVC ratio <70 %
Lung volumes by plethysmography (BOTH):
- Total Lung Capacity (TLC) > 100 % predicted
- Residual Volume (RV) > 150 % predicted
- Diffusing Capacity of Carbon Monoxide(DLco) > = 20 and < = 60 percent predicted
- Oxygen saturation (SpO2) > 90 % on < or = 4 L/min supplemental O2, at rest
- Six-Minute Walk Test distance > or = 150 m
- Abstinence from smoking for at least 16 weeks prior to screening
Exclusion Criteria:
- Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, or prior lung transplantation
- Requirement for ventilator support (invasive or non-invasive)
- Three (3) or more COPD exacerbations requiring hospitalization within 1 year of Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of Screening visit
Pulmonary hypertension, defined as:
- Echocardiogram with estimated peak systolic pressure > 45 mmHg in the presence of tricuspid valve regurgitation stated in the echocardiogram report
- If the echocardiogram shows peak systolic pressure > 45 mmHg, right heart catheterization is required to rule out pulmonary hypertension, defined as peak systolic pressure > 45 mmHg or mean pressure > 35 mmHg
- Clinically significant asthma (reversible airway obstruction) or bronchiectasis
CT scan: Presence of the following radiologic abnormalities:
- Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if present for 2 years or more without increase in size or if proven benign by biopsy/PET)
- Radiologic picture consistent with active pulmonary infection, e.g., unexplained parenchymal infiltrate
- Significant interstitial lung disease
- Significant pleural disease
- Giant bullous disease (a predominant bulla > 10 cm in all dimensions >1 / 3 of the hemithorax)
- Use of systemic steroids > 20 mg/day or equivalent, immunosuppressive agents, heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs including aspirin and clopidogrel are permitted)
- Allergy or sensitivity to medications required to safely undergo AeriSeal System treatment
- Participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the screening visit
- Body mass index < 15 kg/m2 or > 35 kg/m2
- Female patient pregnant or breast-feeding or planning to be pregnant in the next year
Significant comorbidity that carries prohibitive risks or is associated with less than 2-year expected survival, including any of the following:
- HIV/AIDS
- Active malignancy
- Stroke or Transient Ischemia Attack (TIA) within 12 months of screening
- Myocardial infarction within 12 months of screening
- Congestive heart failure within 12 months of screening defined at clinical evidence of right or left hear failure or left ventricular ejection fraction < 45 % on echocardiogram
- Any condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient such as alcoholism, high risk for drug abuse or noncompliance in returning for follow-up visits
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:AeriSeal Emphysematous Lung Sealant Syst
This is a prospective, open label, single-arm, multicenter, investigational study.
Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
|
This is a prospective, open label, single-arm, multicenter, investigational study.
Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Volume change by CT
時間枠:28 - 30 weeks
|
Group mean normalized change from baseline in the volume of the treated lung lobes measured by quantitative CT at 24 weeks post-treatment (defined as the sum of volume change in all treated lobes/number of treatments).
|
28 - 30 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fraction of patients showing clinically significant improvements from baseline in one or more of the following outcomes at 24 weeks post treatment: Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), Medical Research Council Dyspnea
時間枠:28 - 30 weeks
|
Group mean change in baseline to week 24 in:Forced Expiratory Volume in 1 second (FEV1),Forced Vital Capacity (FVC),Medical Research Council Dyspnea (MRCD), 6 Six-Minute Walk Test (6MWT), Saint George Respiratory Questionnaire (SGRQ)
|
28 - 30 weeks
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Felix Herth, Prof. Dr med、Thoraxklinik am Uniklinikum Heidelberg
- 主任研究者:Wolfgang Gesierich, Dr med、Asklepios Fachkliniken Muenchen - Gauting
- 主任研究者:Manfred Wagner, Dr med、Klinikum Nuernberg Nord
- 主任研究者:Mordechai Kramer, Prof、Rabin Medical Center
- 主任研究者:Martin Hetzel, Dr med、Krankenhaus vom Roten Kreuz - Stuttgart
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (予想される)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 03-C13-001PLV
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。